Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review
Nan Yao,Wenqiang Li,Ning Duan,Guoshuai Xu,Guoyong Yu,Jun Qu
DOI: https://doi.org/10.1097/md.0000000000036957
IF: 1.6
2024-01-13
Medicine
Abstract:Gastrointestinal (GI) cancers, which assail the digestive tract, have a significant presence in the global cancer landscape due to their prevalence and mortality rates. [ 1 ] This group includes cancers of the esophagus, stomach, liver, pancreas, gallbladder, and colorectum. Despite advancements in early detection and treatments such as surgery, radiation, and chemotherapy, the prognosis remains poor for many, especially those diagnosed at advanced stages. [ 2 , 3 ] In recent times, immunotherapy has risen to the forefront of cancer treatments, offering hope for numerous cancer types, including GI cancers. [ 4 ] Immunotherapy harnesses the body immune system to detect and eliminate malignant cells. Its range of therapies includes immune checkpoint inhibitors (ICIs), cancer vaccines, and the innovative method of adoptive cell transfer (ACT). [ 5–7 ] These treatments have yielded promising outcomes in various cancers, such as lung cancer, [ 8 , 9 ] breast cancer, [ 10 ] and melanoma, [ 11 , 12 ] resulting in sustained responses and enhanced survival for some patients. However, the effectiveness of immunotherapy for GI cancers has not been as pronounced, especially when compared to its notable successes in treating cancers like melanoma and lung cancer. [ 13 ] A significant challenge is the development of drug resistance, where cancer cells cleverly adapt, continuing to grow, and spread despite immunotherapeutic interventions. [ 14 , 15 ] This resistance can be present from the start of treatment (intrinsic resistance) or may develop as treatment progresses (acquired resistance). [ 16 ] It's crucial to understand the mechanisms of drug resistance in GI cancer immunotherapy. This understanding helps predict patient responses to treatment and drives the development of innovative strategies to overcome resistance. This review highlights the current understanding of immunotherapy in GI cancer, drug resistance mechanisms in GI cancer immunotherapy, with a focus on the role of methods in overcoming drug resistance. The review also discusses current strategies and future directions in overcoming drug resistance in GI cancer immunotherapy.
medicine, general & internal